Xeris Biopharma Holdings, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. -0.40%242.341.5%$875.65m
MRNAModerna, Inc. 5.11%150.150.0%$811.77m
VRTXVertex Pharmaceuticals, Inc. 0.30%282.641.9%$481.28m
GILDGilead Sciences, Inc. -0.30%61.631.0%$474.01m
REGNRegeneron Pharmaceuticals, Inc. -0.40%588.772.6%$469.78m
NVAXNovavax, Inc. 10.83%57.0075.7%$441.68m
ILMNIllumina, Inc. 1.54%187.203.3%$341.04m
SNSSSunesis Pharmaceuticals, Inc. -1.03%3.840.7%$268.43m
BIIBBiogen, Inc. 1.24%206.461.8%$241.01m
BNTXBioNTech SE 4.26%155.450.0%$195.13m
CRSPCRISPR Therapeutics AG 3.26%62.750.6%$165.30m
BMRNBioMarin Pharmaceutical, Inc. 0.70%83.454.2%$116.99m
EXASEXACT Sciences Corp. 2.36%40.3217.7%$93.08m
IOVAIovance Biotherapeutics, Inc. 2.94%11.370.0%$90.74m
TECHBio-Techne Corp. 0.41%348.054.5%$89.98m

Company Profile

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.